1、 KANZLER S,LOHR H,GERKEN G,et al.Long-term management and prognosis of autoimmune hepatitis(AIH):a single center experience[J].Z Gastroenterol,2001,39(5):339-341,344-348. KANZLER S,LOHR H,GERKEN G,et al.Long-term management and prognosis of autoimmune hepatitis(AIH):a single center experience[J].Z Gastroenterol,2001,39(5):339-341,344-348.
2、 FERRI S,LONGHI M S,DE MOLO C,et al.A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis[J].Hepatology,2010,52(3):999-1007. FERRI S,LONGHI M S,DE MOLO C,et al.A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis[J].Hepatology,2010,52(3):999-1007.
3、 JOAO M,CARVALHANA S,MOURA M,et al.Severe acute autoimmune hepatitis:How to early predict who will not respond to corticosteroids and needs urgent liver transplantation?[J].Dig Liver Dis,2022,54(12):1681-1685. JOAO M,CARVALHANA S,MOURA M,et al.Severe acute autoimmune hepatitis:How to early predict who will not respond to corticosteroids and needs urgent liver transplantation?[J].Dig Liver Dis,2022,54(12):1681-1685.
4、 WEBB G J,RANA A,HODSON J,et al.Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists[J].Clin Gastroenterol Hepatol,2018,16(2):278-287.e277. WEBB G J,RANA A,HODSON J,et al.Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists[J].Clin Gastroenterol Hepatol,2018,16(2):278-287.e277.
5、 WANG H,BANERJEE N,LIANG Y,et al.Gut microbiome-host interactions in driving environmental pollutant trichloroethene-mediated autoimmunity[J].Toxicol Appl Pharmacol,2021(424):115597. WANG H,BANERJEE N,LIANG Y,et al.Gut microbiome-host interactions in driving environmental pollutant trichloroethene-mediated autoimmunity[J].Toxicol Appl Pharmacol,2021(424):115597.
6、 LIANG M,LIWEN Z,JIANGUO S,et al.Fecal microbiota transplantation controls progression of experimental autoimmune hepatitis in mice by modulating the TFR/TFH immune imbalance and intestinal microbiota composition[J].Front Immunol,2021(12):728723. LIANG M,LIWEN Z,JIANGUO S,et al.Fecal microbiota transplantation controls progression of experimental autoimmune hepatitis in mice by modulating the TFR/TFH immune imbalance and intestinal microbiota composition[J].Front Immunol,2021(12):728723.
7、 ZHANG H,LIU M,LIU X,et al.Bifidobacterium animalis ssp.Lactis 420 mitigates autoimmune hepatitis through regulating intestinal barrier and liver immune cells[J].Front Immunol,2020(11):569104. ZHANG H,LIU M,LIU X,et al.Bifidobacterium animalis ssp.Lactis 420 mitigates autoimmune hepatitis through regulating intestinal barrier and liver immune cells[J].Front Immunol,2020(11):569104.
8、 LIU Q,TIAN H,KANG Y,et al.Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability[J].J Nutr Biochem,2021(98):108863. LIU Q,TIAN H,KANG Y,et al.Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability[J].J Nutr Biochem,2021(98):108863.
9、 ARVANITI P,GIANNOULIS G,GABETA S,et al.Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis[J].JHEP Rep,2020,2(4):100123. ARVANITI P,GIANNOULIS G,GABETA S,et al.Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis[J].JHEP Rep,2020,2(4):100123.
10、 THAN N N,HODSON J,SCHMIDT-MARTIN D,et al.Efficacy of rituximab in difficult-to-manage autoimmune hepatitis:Results from the international autoimmune hepatitis group[J].JHEP Rep,2019,1(6):437-445. THAN N N,HODSON J,SCHMIDT-MARTIN D,et al.Efficacy of rituximab in difficult-to-manage autoimmune hepatitis:Results from the international autoimmune hepatitis group[J].JHEP Rep,2019,1(6):437-445.
11、 HUBENER S,OO Y H,THAN N N,et al.Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance[J].Clin Gastroenterol Hepatol,2016,14(3):445-453. HUBENER S,OO Y H,THAN N N,et al.Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance[J].Clin Gastroenterol Hepatol,2016,14(3):445-453.
12、 HARIDY J,NICOLL A,SOOD S.Methotrexate therapy for autoimmune hepatitis[J].Clin Gastroenterol Hepatol,2018,16(2):288-289. HARIDY J,NICOLL A,SOOD S.Methotrexate therapy for autoimmune hepatitis[J].Clin Gastroenterol Hepatol,2018,16(2):288-289.
13、 BAVEN-PRONK M A,HEW J M Jr,BIEWENGA M,et al.Calcineurin inhibitors in the treatment of adult autoimmune hepatitis:A systematic review[J].J Clin Transl Hepatol,2022,10(6):1155-1166. BAVEN-PRONK M A,HEW J M Jr,BIEWENGA M,et al.Calcineurin inhibitors in the treatment of adult autoimmune hepatitis:A systematic review[J].J Clin Transl Hepatol,2022,10(6):1155-1166.
14、 SANTIAGO P,SCHWARTZ I,TAMARIZ L,et al.Systematic review with meta-analysis:mycophenolate mofetil as a second-line therapy for autoimmune hepatitis[J].Aliment Pharmacol Ther,2019,49(7):830-839. SANTIAGO P,SCHWARTZ I,TAMARIZ L,et al.Systematic review with meta-analysis:mycophenolate mofetil as a second-line therapy for autoimmune hepatitis[J].Aliment Pharmacol Ther,2019,49(7):830-839.
15、 de LEMOS-BONOTTO M,VALLE-TOVO C,COSTABEBER A M,et al.A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment[J].Eur J Gastroenterol Hepatol,2018,30(2):212-216. de LEMOS-BONOTTO M,VALLE-TOVO C,COSTABEBER A M,et al.A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment[J].Eur J Gastroenterol Hepatol,2018,30(2):212-216.
16、 MANNS M P,WOYNAROWSKI M,KREISEL W,et al.Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J].Gastroenterology,2010,139(4):1198-1206. MANNS M P,WOYNAROWSKI M,KREISEL W,et al.Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J].Gastroenterology,2010,139(4):1198-1206.
17、 BJORNSSON H K,GUDBJORNSSON B,BJORNSSON E S.Infliximab-induced liver injury:Clinical phenotypes,autoimmunity and the role of corticosteroid treatment[J].J Hepatol,2022,76(1):86-92. BJORNSSON H K,GUDBJORNSSON B,BJORNSSON E S.Infliximab-induced liver injury:Clinical phenotypes,autoimmunity and the role of corticosteroid treatment[J].J Hepatol,2022,76(1):86-92.
18、 VOLLMER O,FELTEN R,MERTZ P,et al.Characterization of auto-immune hepatitis associated with the use of anti-TNFalpha agents:An analysis of 389 cases in VigiBase[J].Autoimmun Rev,2020,19(3):102460. VOLLMER O,FELTEN R,MERTZ P,et al.Characterization of auto-immune hepatitis associated with the use of anti-TNFalpha agents:An analysis of 389 cases in VigiBase[J].Autoimmun Rev,2020,19(3):102460.
19、 LIN R,ZHOU L,ZHANG J,et al.Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160. LIN R,ZHOU L,ZHANG J,et al.Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160.
20、 LIWINSKI T,CASAR C,RUEHLEMANN M C,et al.A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J].Aliment Pharmacol Ther,2020,51(12):1417-1428. LIWINSKI T,CASAR C,RUEHLEMANN M C,et al.A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis[J].Aliment Pharmacol Ther,2020,51(12):1417-1428.
21、 WEI Y,LI Y,YAN L,et al.Alterations of gut microbiome in autoimmune hepatitis[J].Gut,2020,69(3):569-577. WEI Y,LI Y,YAN L,et al.Alterations of gut microbiome in autoimmune hepatitis[J].Gut,2020,69(3):569-577.
22、 ELSHERBINY N M,RAMMADAN M,HASSAN E A,et al.Autoimmune hepatitis:shifts in gut microbiota and metabolic pathways among Egyptian patients[J].Microorganisms,2020,8(7):1011. ELSHERBINY N M,RAMMADAN M,HASSAN E A,et al.Autoimmune hepatitis:shifts in gut microbiota and metabolic pathways among Egyptian patients[J].Microorganisms,2020,8(7):1011.
23、 LOU J,JIANG Y,RAO B,et al.Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals[J].Front Cell Infect Microbiol,2020(10):342. LOU J,JIANG Y,RAO B,et al.Fecal microbiomes distinguish patients with autoimmune hepatitis from healthy individuals[J].Front Cell Infect Microbiol,2020(10):342.
24、 LOHSE A W,SEBODE M,BHATHAL P S,et al.Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH pathology group:Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology[J].Liver Int,2022,42(5):1058-1069. LOHSE A W,SEBODE M,BHATHAL P S,et al.Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH pathology group:Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology[J].Liver Int,2022,42(5):1058-1069.
25、 MACK C L,ADAMS D,ASSIS D N,et al.Diagnosis and management of autoimmune hepatitis in adults and children:2019 practice guidance and guidelines from the American association for the study of liver diseases[J].Hepatology,2020,72(2):671-722. MACK C L,ADAMS D,ASSIS D N,et al.Diagnosis and management of autoimmune hepatitis in adults and children:2019 practice guidance and guidelines from the American association for the study of liver diseases[J].Hepatology,2020,72(2):671-722.
26、 MIELI-VERGANI G,VERGANI D,BAUMANN U,et al.Diagnosis and management of pediatric autoimmune liver disease:ESPGHAN Hepatology Committee Position Statement[J].J Pediatr Gastroenterol Nutr,2018,66(2):345-360. MIELI-VERGANI G,VERGANI D,BAUMANN U,et al.Diagnosis and management of pediatric autoimmune liver disease:ESPGHAN Hepatology Committee Position Statement[J].J Pediatr Gastroenterol Nutr,2018,66(2):345-360.
27、 GATSELIS N K,AZARIADIS K,LYBEROPOULOU A,et al.Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis[J].J Transl Autoimmun,2021(4):100126. GATSELIS N K,AZARIADIS K,LYBEROPOULOU A,et al.Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis[J].J Transl Autoimmun,2021(4):100126.
28、 de BOER Y S,van GERVEN N M,ZWIERS A,et al.Genome-wide association study identifies variants associated with autoimmune hepatitis type 1[J].Gastroenterology,2014,147(2):443-452.e5. de BOER Y S,van GERVEN N M,ZWIERS A,et al.Genome-wide association study identifies variants associated with autoimmune hepatitis type 1[J].Gastroenterology,2014,147(2):443-452.e5.
29、 TAUBERT R,ENGEL B,DIESTELHORST J,et al.Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis[J].Hepatology,2022,75(1):13-27. TAUBERT R,ENGEL B,DIESTELHORST J,et al.Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis[J].Hepatology,2022,75(1):13-27.
30、 中华医学会肝病学分会.自身免疫性肝炎诊断和治疗指南(2021)[J].中华肝脏病杂志,2022,30(5):482-492. 中华医学会肝病学分会.自身免疫性肝炎诊断和治疗指南(2021)[J].中华肝脏病杂志,2022,30(5):482-492.
